Genesiscare UK and Oxford University Hospital, Oxford, UK
Genesiscare UK.
Clin Med (Lond). 2023 Jan;23(1):61-64. doi: 10.7861/clinmed.2022-0559.
Most cancer-related deaths are due to metastatic disease. There is now an emerging evidence base suggesting that a subgroup of metastatic patients benefit significantly from local resection (surgery) or ablation (stereotactic ablative body radiation, SABR) of their metastatic sites. These patients are in what has been termed the 'oligometastatic state', a transitional window between local and disseminated disease where locally ablative, metastasis-directed therapy prolongs progression-free survival, improves overall survival and sometimes achieves cure. Appropriately selecting those who fit this oligometastatic phenotype, while integrating advances in ablative technologies such as SABR with modern systemic treatments, is an evolving challenge for oncologists.
大多数与癌症相关的死亡都是由于转移疾病引起的。现在有越来越多的证据表明，一小部分转移性患者从转移性部位的局部切除（手术）或消融（立体定向消融体放射治疗，SABR）中显著获益。这些患者处于所谓的“寡转移状态”，这是局部和播散性疾病之间的过渡窗口，局部消融、针对转移灶的治疗可延长无进展生存期、改善总生存期，有时还可实现治愈。为了应对这一挑战，肿瘤学家需要适当地选择那些符合寡转移表型的患者，同时将 SABR 等消融技术的进步与现代系统治疗相结合。
